Information Library
Results for: Cardiovascular - ECG
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
The Contribution of Early-phase Clinical Data to a Drug’s Integrated Cardiac Safety Portfolio
Hear from the Experts — January 16, 2012
This article examines the financial and time benefits to incorporating intensive ECG and QT/QTc monitoring in early-phase clinical studies. -
The Contribution of Early-phase Clinical Data to a Drug’s Integrated Cardiac Safety Portfolio
Hear from the Experts — December 6, 2011
This article examines the financial and time benefits to incorporating intensive ECG and QT/QTc monitoring in early-phase clinical studies. -
CardioCheck
White Paper — May 10, 2011
Quintiles' CardioCheck program is designed to provide rapid insight into potential cardiotoxic influences of pharmaceutical compounds. -
Clinical – Smarter Trials, Accelerated Outcomes
Brochure — February 16, 2011
Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues. -
Podcast: Cardiac Safety in Clinical Research
Hear from the Experts — September 24, 2010
J.Rick Turner, Ph.D., Senior Scientific Director, Cardiac Safety Services at Quintiles, discusses the importance of cardiovascular assessments in clinical development. -
EMA’s Guidance on New Antidiabetic Drug Development
White Paper — May 12, 2010
Assessing the EMA’s Guidance on New Antidiabetic Drug Development In January 2010, the European Medicines Agency (EMA) issued a draft guideline on antidiabetic drug development -
TQT Studies: Integrated Cardiac Expertise for Smarter Decisions, Sooner
Brochure — April 13, 2010
At Quintiles, we offer you a complete solution for your TQT needs including our Phase I, Clinical Pharmacology and ECG Core Labs. -
Journal for Clinical Studies
Hear from the Experts — February 19, 2010
In the January 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the FDA Guidance on diabetes drugs and cardiovascular risk. -
New FDA Guidance on Antidiabetic Therapies
White Paper — December 11, 2009
Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.
Page 1 of 1 (9 results)
